Clinical Trial

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-08-16; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2024-05-02
Trial Details
NCT Number NCT06001658
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Merck Sharp & Dohme LLC
Conditions Billiary Track Cancer
Enrollment 27 participants
Start Date 2024-07-08
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-03